RESEARCH

Open Access

The role of small airway function parameters in preschool asthmatic children



Liangqin Yi¹, Yan Zhao¹, Ziyao Guo¹, Qinyuan Li¹, Guangli Zhang², Xiaoyin Tian², Ximing Xu³ and Zhengxiu Luo^{2*}

Abstract

Background Small airways are the major sites of inflammation and airway remodeling in all severities of asthma patients. However, whether small airway function parameters could reflect the airway dysfunction feature in preschool asthmatic children remain unclear. We aim to investigate the role of small airway function parameters in evaluating airway dysfunction, airflow limitation and airway hyperresponsiveness (AHR).

Methods Eight hundred and fifty-one preschool children diagnosed with asthma were enrolled retrospectively to investigate the characteristics of small airway function parameters. Curve estimation analysis was applied to clarify the correlation between small and large airway dysfunction. Spearman's correlation and receiver-operating characteristic (ROC) curves were employed to evaluate the relationship between small airway dysfunction (SAD) and AHR.

Results The prevalence of SAD was 19.5% (166 of 851) in this cross-sectional cohort study. Small airway function parameters (FEF25-75%, FEF50%, FEF75%) showed strong correlations with FEV₁% (r = 0.670, 0.658, 0.609, p<0.001, respectively), FEV₁/FVC% (r = 0.812, 0.751, 0.871, p<0.001, respectively) and PEF% (r = 0.626, 0.635, 0.530, p<0.01, respectively). Moreover, small airway function parameters and large airway function parameters (FEV₁%, FEV₁/FVC%, PEF%) were curve-associated rather than linear-related (p<0.001). FEF25-75%, FEF50%, FEF75% and FEV₁% demonstrated a positive correlation with PC₂₀ (r = 0.282, 0.291, 0.251, 0.224, p<0.001, respectively). Interestingly, FEF25-75% and FEF50% exhibited a higher correlation coefficient with PC₂₀ than FEV₁% (0.282 vs. 0.224, p = 0.031 and 0.291 vs. 0.224, p = 0.014, respectively). ROC curve analysis for predicting moderate to severe AHR showed that the area under the curve (AUC) was 0.796, 0.783, 0.738, and 0.802 for FEF25-75%, FEF50%, FEF75%, and the combination of FEF25-75% and FEF75%, respectively. When Compared to children with normal lung function, patients with SAD were slightly older, more likely to have a family history of asthma and airflow obstruction with lower FEV₁% and FEV₁/FVC%, lower PEF% and more severe AHR with lower PC₂₀ (all p<0.05).

Conclusion Small airway dysfunction is highly correlated with large airway function impairment, severe airflow obstruction and AHR in preschool asthmatic children. Small airway function parameters should be utilized in the management of preschool asthma.

Keywords Asthma, Small airway function, Spirometry, FEF25-75%, FEF50%, FEF75%

*Correspondence:

Zhengxiu Luo

luozhengxiu816@hospital.cqmu.edu.cn

¹Chongqing Key Laboratory of Pediatrics, International Science and Technology Cooperation base of Child Development and Critical Disorders, Department of Children's Hospital of Chongqing Medical, Key Laboratory of Child Development and Disorders, National Clinical



Research Center for Child Health and Disorders, Department of Clinical Laboratory center, University of Education, 400014 Chongqing, China ²National Clinical Research Center for Child Health and Disorders, Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing, China ³Big Data Center for Children's Medical Care, Children's Hospital of Chongqing Medical University, Chongqing, China

© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Asthma is a common chronic airway inflammatory disease affecting the entire bronchial tree. Recurrent and excessive airway inflammation could result in persistent airway epithelial injury, abnormal repairment, and airway remodeling, which accelerates both small and large airway function exacerbation [1]. The main goal of current asthma treatment is to achieve symptom control, and its long-term management aims to maintain optimal lung function [2]. The Global Initiative for Asthma (GINA) has established specific recommendations for spirometry parameters including forced expiratory volume in 1 s (FEV₁) and peak expiratory flow (PEF) [2], which serve as indicators of large airway function and are used in the assessment and management of asthma.

Small airways are defined as the 7th-8th generation airways with an internal diameter of less than 2 mm with no cartilage in their walls [3], have been identified as the main sites of type 2 inflammation and airway remodeling in both adults and children with asthma [4–6]. Small airway dysfunction (SAD) has been associated with worse asthma control [7], increased exacerbations [8, 9], airway inflammation and airway hyperresponsiveness (AHR) [10, 11], increased risk for asthma development [12, 13], and loss of lung function with aging in children [14].

However, large airway function parameters are insensitive to evaluating SAD in the early stage of asthma, especially in most asthmatic children with normal or nearly normal FEV₁% (\geq 80%) [15–17]. Therefore, it is necessary to identify and apply other spirometry parameters for asthmatic children that can evaluate small airway function sensitively. Studies [18-21] have demonstrated that forced expiratory flow between 25% and 75% of forced vital capacity predicted (FEF25-75%), forced expiratory flow at 50% of forced vital capacity predicted (FEF50%) and forced expiratory flow at 75% of forced vital capacity predicted (FEF75%) can be used to evaluate small airway function as these parameters are less effort-dependent than FEV₁, PEF, forced expiratory volume in 1 s/forced expiratory vital capacity ratio (FEV₁/FVC). Although evidence in adults showed a good correlation between large and small airway function [21], the correlation in asthmatic children remains unclear and whether small airway function parameters could reflect airway dysfunction need to be clarified [22, 23]. This study aims to investigate the role of small airway function parameters in evaluating airway dysfunction, airflow limitation and AHR in preschool asthmatic children.

Materials and methods

Patients

The observational, retrospective cohort study was conducted at the Children's Hospital of Chongqing Medical University, a tertiary teaching hospital in Chongqing, China. Preschool children diagnosed with suspected asthma between January 1, 2019 and December 31, 2020 were enrolled retrospectively by reviewing the electronic medical databases from the Department of Respiratory. The inclusion criteria were all of the following: (i) clinical asthma diagnosis for the first time according to GINA guidelines(2018) [2] by at least one pediatric pulmonologist, (ii) age 3–5 years; (iii) the completion of standard lung function test with technically acceptable flow-volume curves [24], (iv) without respiratory infections for 4 weeks before lung function test [25]. The exclusion criterion was any of the following: (i) acute and/or chronic diseases that could affect lung function tests (including bronchiectasis, pulmonary tuberculosis, interstitial lung disease, heart failure, severe psychiatric disorders, etc.); (ii) use of anti-asthma therapy (including inhaled corticosteroids, leukotriene receptor antagonist and long-acting beta-agonists)≥4 weeks or other medications that affecting lung function test [26, 27]. (iii) with poor-quality spirometric data.

Lung function test and definitions

Spirometry (Masterscreen Paediatric; PFT) was performed according to the guidelines of the American Thoracic Society(ATS) and or European Respiratory Society (ERS) [24] by trained technicians at the lung function laboratory. Short-acting beta-agonists should be stopped at least 4 h, while long-acting beta-agonists should be stopped at least 12 h and inhaled corticosteroids should be discontinued at least 24 h before the performance of spirometry or either a bronchial provocation test (using methacholine) or a bronchodilator test (using salbutamol). Whether a bronchial provocation test was conducted depended on the patients' condition (including $FEV_1 \ge 70\%$ and without dyspnea). All lung function tests were repeated at least three times to ensure reproducibility, and the best FVC maneuver from the three attempts was chosen. The professional investigator reviewed the volume-time and flow-volume tracings and exclude poor measurements. Reference values of spirometry parameters for children have been adjusted for age, height and sex [28]. Pre-bronchial provocation or pre-bronchodilator spirometry parameters and the value of the provocative concentration of methacholine that caused a 20% fall in FEV_1 (PC₂₀) were recorded and included in this analysis.

Airflow obstruction was defined by FEV₁% and FEV₁/FVC% [25, 29]. Specifically, normal (FEV₁%≥80% and accompanied with FEV₁/FVC% ≥ 92%), mild (70% ≤ FEV₁%<80% or FEV₁≥80% but FEV₁/FVC%<92%), moderate (60% ≤ FEV₁%<70%), moderate to severe (50% ≤ FEV₁%<60%), severe (35% ≤ FEV₁%<50%) and extremely severe (FEV₁%<35%).

The degree of AHR was categorized into three levels based on the PC₂₀ [30, 31], borderline AHR ($4 \text{ g/L} < \text{PC}_{20} \le 16 \text{ g/L}$), mild AHR ($1 \text{ g/L} < \text{PC}_{20} \le 4 \text{ g/L}$), and moderate to severe AHR (PC₂₀ $\le 1 \text{ g/L}$).

FEV₁% was used to assess large airway function, and its lower limit value is 80%. FEF25-75%, FEF50%, and FEF75% were used to evaluate small airway function, and their lower limit value is 65%. According to previous studies [18, 21] especially in the Chinese characteristics [28], SAD was defined as any two of these three small airway function parameters being<65% accompanied by FEV₁% ≥ 80% [32]. Normal lung function (NLF) was defined as FEV₁%≥80% and at least two of FEF25-75%, FEF50% and FEF75% ≥ 65%. Large airway dysfunction (LAD) was defined as FEV₁%<80% and at least two of FEF25-75%, FEF50% and FEF75% ≥ 65%. Both large and small airway dysfunction (LSAD) was defined as FEV₁%<80% and at least two of FEF25-75%, FEF50% and FEF75%<65%.

If there was at least one positive response to the common aeroallergens (house dust mites, cotton, cat and dog fur and birch, etc.) and food allergens (peanuts, milk, egg, mango, and shrimp, etc.) by skin prick test, a child were considered atopic [21]. Eosinophilia was defined as a patient having a peripheral blood eosinophil count of $\geq 0.5 \times 10^9$ /L and eosinophils comprising $\geq 5\%$ of leukocytes [33].

Data collection

Patients' data were collected from the medical records by two trained researchers independently, using a standard collection form. A third researcher assisted in the data extraction if any disagreement existed. Demographic characteristics (sex, age, weight, height and body mass index (BMI)), family history of asthma (maternal and paternal history), comorbidity (allergic rhinitis and eczema), peripheral eosinophil count and proportion, skin prick test results, and baseline values of FVC, FEV₁, FEV₁/FVC, PEF, FEF25 (forced expiratory flow at 25% of FVC), FEF50, FEF75, FEF25-75 and PC₂₀ were collected. All spirometry parameters were expressed as a percentage of predicted values (%pred).

Statistical analysis

The distribution of continuous variables was assessed by the Shapiro-Wilk test, and continuous variables were expressed as the median and interquartile range (IQR), while categorical variables were presented as numbers and percentages (%). Continuous variables were assessed by the non-parametric Mann-Whitney U test, and Categorical variables were compared using the chi-square test with Fisher exact test or Monte Carlo method. Bonferroni correction was applied when multiple means needed to be compared. The prevalence of FEF25-75%, FEF50%, and FEF75% between subgroups was compared using the related samples Cochran's test and McNemar's test. Spearman's correlation and correlation coefficient comparison analysis were used to evaluate the variables' relation. Additionally, Curve Estimation analysis was performed for large airway function parameters (FEV₁%, FEV₁/FVC%, PEF%) and small airway function parameters (FEF25-75%, FEF50%, FEF75%) in the overall group and subgroups, which included 11 models: Linear, Logarithmic, Inverse, Quadratic, Cubic, Compound, Power, S, Growth, Exponential, and Logistic model. The bestfitting model was used to present the correlation among variables. Receiver-operating characteristic (ROC) curves were constructed to estimate the ability of small airway parameters in predicting AHR.

All data analyses were performed using the IBM SPSS software for Windows, (version 26.0 SPSS Inc. Chicago, IL, USA). A *p*-value of <0.05 (two-tailed) was considered statistically significant. All graphics were completed by GraphPad Prism (Version 9.0.0 San Diego, California, USA).

Results

Characteristics

The medical record database of the Department of Respiratory at the Children's Hospital of Chongqing Medical University was screened. From January 1, 2019, to December 31, 2020, a total of 6412 preschool children with suspected asthma who presented with recurrent wheezing with or without chronic cough were identified and assessed in respiratory clinics. Out of these, 6149 children were diagnosed with bronchial asthma. Finally, 851 preschool asthmatic children who met the inclusion and exclusion criteria were enrolled in the study (Fig. 1).

In this study cohort, the median age of those 851 preschool asthmatics was 4.3 years old, and boy predominance of 57.5% (489 of 851). The majority of the children (91.5%, 779 of 851) had normal FEV1% (≥80%) and FEV1/ FVC% (>70%). The prevalence of abnormal small airway function parameters (FEF25-75%, FEF50%, FEF75%) was 25.4% (261 of 851), 27.4% (233 of 851), and 36.4% (310 of 851), respectively. The prevalence of SAD was 19.5% (166 of 851), the prevalence of NLF, LAD and LASD was 72.0% (613 of 851), 0.7% (6 of 851) and 7.8% (66 of 851), respectively. FEF75% showed the highest abnormal rate compared to FEF25-75% and FEF50% among the overall, NLF and SAD groups in preschool asthmatic children (p<0.001, as shown in Additional file 1: Appendix Fig. 1). Most of the patients had normal pulmonary ventilation (86.0%, 732/851), with mild, moderate, moderate to severe, severe and extremely severe airflow obstruction accounting for 10.0% (85/851), 1.9% (16/851), 1.6% (14/851), 0.4% (3/851), 0.1% (1/851), respectively. Among the 753 preschool children who performed bronchial Flow diagram of study progression.



*Anti-asthma treatment: including Inhaled corticosteroids and leukotriene receptor antagonist.

Fig. 1 Flow diagram of study progression

provocation tests, 40.1% (302), 52.7% (397), and 7.2% [54] had borderline, mild, and moderate to severe AHR, respectively. More demographic, history and lung function information for this cohort was presented in Table 1.

In the subgroups, asthmatic children in the SAD group were slightly elder, more likely to have a family asthmatic history, and severe airflow obstruction, as well as decreased PEF% and a higher degree of AHR with lower PC_{20} value as compared to NLF group. A similar tendency was observed in the comparison of the NLF and LSAD groups (p<0.005, Table 2). Furthermore, preschool patients in the NLF and SAD groups had normal FEV₁% (\geq 80%), but patients in the SAD group had significantly lower FEV₁% than those in the NLF group, as well as lower FEV₁/FVC%, PEF% (p<0.001, Fig. 2a, b, c). Interestingly, patients with LSAD had the lowest

Table 1Demographic and lung function parameters inpreschool asthmatic children (N=851)

Characteristics	Median (P25, P75) or Num- ber (%)
Age of asthma onset (y)	4.3 (3.9, 5.0)
Sex (boy)	489 (57.5)
BMI	16.0 (15.2,
	17.0)
Family and personal history	
Parental wheeze	82 (9.6)
allergic rhinitis	412 (48.4)
eczema	226 (26.6)
atopy	489 (57.5)
Blood eosinophil test	483 (56.8)
Eosinophilia	190 (39.3)
Spirometry	
Patients with FEV₁%≥80%	779 (91.5)
Patients with FEF25-75%<65%	216 (25.4)
Patients with FEF75%<65%	310 (36.4)
Patients with FEF50%<65%	233 (27.4)
Normal lung function (NLF)	613 (72.0)
Large airway dysfunction (LAD)	6 (0.7)
Small airway dysfunction (SAD)	166 (19.5)
Large and small airway dysfunction (LSAD)	66 (7.8)
FVC%	94.3
	(86.7,103.7)
FEV1%	98.9
	(90.2,108.0)
FEV ₁ /FVC%	104.9
	(99.0,110.7)
PEF%	85.4 (76.2,96.3)
FEF25%	84.5 (73.7,96.4)
FEF50%	80.0 (63.5,96.8)
FEF/5%	/3.4 (55.0,96.6)
FEF25-75%	81.0 (64.5,99.3)
Airflow Obstruction	
normal	732 (86.0)
mild	85 (10.0)
moderate	16 (1.9)
moderate to severe	14 (1.6)
severe	3 (0.4)
extremely severe	1 (0.1)
Patients with bronchial provocation testing	753 (88.5)
PC ₂₀ (g/L)	2.0 (2.0,8.0)
Airway Hyperresponsiveness (AHR)	753 (88.5)
Borderline	302 (40.1)
Moderate to severe	597 (52.7) 54 (7 2)
	- · 、 · · - /

BMI, Body mass index; FVC%, forced expiratory vital capacity in predicted; FEV₁%, forced expiratory volume in 1 s in predicted; FEV₁/ FVC%, forced expiratory vital capacity/forced expiratory vital capacity ratio; PEF%, peak expiratory flow in predicted; FEF25%, forced expiratory flow at 25% of FVC predicted; FEF50%, forced expiratory flow at 50% of FVC predicted; FEF55%, forced expiratory flow at 75% of FVC predicted; FEF25%, forced expiratory flow between 25% and 75% of FVC predicted; PC₂₀, value of the provocative concentration of methacholine that causing a 20% fall in FEV₁; AHR: Airway hyperresponsiveness.

FEF25-75%, FEF50%, and FEF75% among subgroups ((p<0.001,Fig. 2d, e, f). However, there were no differences among subgroups in terms of gender, history of allergic rhinitis, eczema, eosinophilia and atopic status (p>0.05).

The correlation between FEF25-75%, FEF50%, FEF75% and FEV1%, FEV1/FVC%, PEF%

Spearman's correlation analysis revealed a relatively strong association between small and large airway function parameters. FEF25-75%, FEF50% and FEF75% were significantly correlated with FEV₁% with a spearman coefficient of 0.670 (95%CI 0.629-0.710), 0.658 (95%CI 0.612-0.698) and 0.609 (95%CI 0.562-0.655), respectively (all p<0.001, see Fig. 3a1 and Additional File 2: Appendix Table 1). Similarly, FEF25-75%, FEF50% and FEF75% were correlated with FEV₁/FVC% with a spearman coefficient of 0.812 (95%CI 0.786-0.838), 0.751 (95%CI 0.720-0.783) and 0.871 (95%CI 0.851-0.888), respectively (p<0.001, see Fig. 3a2 and Additional File 3: Appendix Table 2). Additionally, FEF25-75%, FEF50% and FEF75% were correlated with PEF% with a Spearman coefficient of 0.626 (95%CI 0.518-0.669), 0.635 (95%CI 0.589-0.676) and 0.530 (95%CI 0.481-0.579), respectively (p<0.01, see Fig. 3a3 and Additional File 4: Appendix Table 3). Furthermore, curve estimation analysis showed there was no linear relationship among FEF25-75%, FEF50% and FEF75% and FEV1%, FEV1/FVC% and PEF% (p<0.001, see Fig. 3a1-a3 and Additional File 5: Appendix Table 4 A to I for model comparisons).

Similar associations were observed in subgroups. Specifically, FEF25-75% showed a significant correlation with FEV₁ in the NLF group (Spearman coefficient 0.419, 95%CI 0.344-0.485), the SAD group (Spearman coefficient 0.469, 95%CI 0.338-0.573), and the LSAD group (Spearman coefficient 0.553, 95%CI 0.364-0.693) (p<0.001). In the SAD group, FEF25-75% was significantly and robustly correlated with FEV₁%, FEV₁/FVC% and PEF% among small airway parameters (p < 0.05). Similarly, FEF75% was significantly correlated with FEV₁/FVC% with a Spearman coefficient of 0.811 (95%CI 0.780-0.838) in the NLF group, 0.601 (95%CI 0.495-0.701) in SAD group and 0.593 (95%CI 0.365-0.772) in LSAD group, respectively, (p < 0.001). (All data were presented in Fig. 3b to e and Appendix Tables 1, 2 and 3). Moreover, the optimal models to show the correlation trends between variables in subgroups were presented in Fig. 3b to e (See Additional File 5: Appendix Table 4 A to I for detailed model comparisons).

The correlation with PC_{20} and AHR in small airway function parameters

In 753 preschool patients who had performed bronchial provocation test, results demonstrated that FEV_1 %,

Characteristics	Overall	NLF	LAD	SAD	LSAD	P value	P value	P value
	N = 851	N=613	N=6	N = 166	N = 66	(Subgroups)	(NLF vs. SAD)	(NLF vs.
	(100.0)	(1/2.0)	(0.7)	(C.61)	(8.1)			LSAU)
Age of asthma onset (y)	4.3 (3.9,5.0)	4.3 (3.8,4.9)	4.5 (3.8,5.0)	4.5 (4.0,5.3)	4.6 (4.1,5.1)	<0.001	0.002	0.024
Sex (boy)	489 (57.5)	347 (56.6)	5 (83.3)	100 (60.2)	37 (56.1)	0.519 [†]	0.401	0.932
BMI	16.0 (15.2,17.0)	16.1 (15.2,17.1)	15.7 (14.5,16.8)	16.0 (15.2,17.0)	15.5 (14.6,16.4)	0.026	1.000	0.020
Family and Personal History								
Parental wheeze	82 (9.6)	51 (8.3)	0 (0.0)	25 (15.1)	6 (9.1)	0.076 [†]	0.009	0.830
Allergic rhinitis	412 (48.4)	295 (48.1)	4 (66.7)	84 (50.6)	29 (43.9)	0.647*	0.571	0.518
Eczema	226 (26.6)	165 (26.9)	3 (50.0)	39 (23.5)	19 (28.8)	0.402 [†]	0.374	0.745
Atopy	489 (57.5)	360 (76.3)	2 (66.7)	91 (70.0)	36 (76.6)	0.437*	0.144	0.960
Eosinophilia	190 (39.3)	137 (39.5)	2 (40.0)	33 (37.1)	18 (42.9)	0.936 [†]	0.678	0.739
Parameters of spirometry								
FVC%	94.3 (86.7,103.7)	96.0 (88.8,105.4)	69.0 (68.5,73.4)	94.8 (88.1,102.0)	75.0 (61.8,81.8)	< 0.001	1.000	<0.001
FEV ₁ %	98.9 (90.2,108.0)	103.4 (95.8,111.8)	78.4 (75.6, 79.7)	90.1 (83.9,97.2)	69.0 (58.1,76.5)	< 0.001	<0.001	<0.001
FEV1/FVC%	104.9 (99.0,110.7)	107.8 (103.5,111.8)	108.8 (106.2,113.3)	95.7 (91.1,98.8)	95.6 (87.8,102.5)	< 0.001	<0.001	<0.001
PEF%	85.4 (76.2,96.3)	89.5 (81.5,99.7)	78.0 (65.2,80.4)	77.9 (71.4,86.1)	62.2 (51.9,70.9)	< 0.001	<0.001	<0.001
FEF25%	84.5 (73.7,96.4)	90.6 (81.5,100.9)	75.9 (66.8, 80.4)	71.2 (65.3,77.2)	54.5 (45.2,63.6)	< 0.001	<0.001	< 0.001
FEF50%	80.0 (63.5,96.8)	89.3 (77.1,103.4)	70.6 (67.7,7.0)	58.0 (51.9,62.1)	42.4 (36.1,50.2)	< 0.001	<0.001	< 0.001
FEF75%	73.4 (55.0,96.6)	84.1 (70.1,106.1)	81.8 (64.7,86.2)	47.6 (42.1,54.3)	34.1 (27.3,43.8)	< 0.001	<0.001	<0.001
FEF25-75%	81.0 (64.5,99.3)	90.4 (77.5,105.1)	79.0 (73.6,81.7)	56.3 (51.2,61.9)	42.0 (32.3,50.0)	< 0.001	<0.001	<0.001
Airflow obstruction						<0.001 ⁺	<0.001	<0.001
Normal	732 (86.0)	611 (99.7)	0	121 (72.9)	0			
Mild	85 (10.0)	2 (0.3)	6 (100.0)	45 (27.1)	32 (48.5)			
Moderate	16 (1.9)	0	0	0	16 (24.2)			
Moderate to severe	14 (1.6)	0	0	0	14 (21.2)			
Severe	3 (0.4)	0	0	0	3 (4.5)			
Extremely Severe	1 (0.1)	0	0	0	1 (1.5)			
PC ₂₀ (g/L)	2.0 (2.0,8.0)	2.0 (2.0,8.0)	8.0 (1.3,8.0)	2.0 (2.0,8.0)	2.0 (0.5,2.0)	<0.001	0.001	0.001
AHR [‡]						<0.001 ⁺	<0.001	<0.001
Borderline	302 (40.1)	248 (43.4)	3 (60.0)	46 (30.9)	5 (18.5)			
Mild	397 (52.7)	302 (52.8)	1 (20.0)	81 (54.4)	13 (48.1)			
Moderate to severe	54 (7.2)	22 (3.8)	1 (20.0)	22 (14.8)	9 (33.3)			
BMI, Body mass index; FVC%, forced PEF% neak expiratory flow in predir	l expiratory vital capacity i -ted: FFF35% forced exnira	n predicted; FEV ₁ %, forced	expiratory volume in 1 s in dicted: EFF50% forced evi	predicted; FEV _{1/} FVC%,	FEV ₁ /FVC%, forced expira VC predicted: FFF75% for	itory vital capacity/forc	ed expiratory vital ca	oacity ratio; FFF25-75%
forced expiratory flow between 25' population, NLF, normal lung functi	% and 75% of FVC predicte ion; LAD, large airway dysfi	ed; PC ₂₀ , value of the provo unction; SAD; small airway	dysfunction; LSAD, large a	nethacholine that causin nd small airway dysfunc	ig a 20% fall in FEV ₁ ; AHR tion; P-value calculated u	: Airway hyperresponsi sing chi-square test (fo	iveness; Overall, the v or categorical variable	vhole study s) or Mann-
Whitney U test (for continuous varia	ables); [†] , data comparison c	of subgroups using Fisher e:	xact test or Monte Carlo m	ethod (corrected by Bor	nferroni test); [‡] , analysis in	i patients with bronchia	al provocation test.	

4 = 2 ÷ <u>.</u> Ē Tahle 2 Clinical



Fig. 2 Comparison of spirometry parameters values among overall and subgroups. — Represent sprometric parameter, Spearman correlation coefficient, p; a1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in overall group; a2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in overall group; b1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in overall group; b1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in NLF group; b2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in NLF group; b3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in NLF group; b3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in LAD group; c2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in LAD group; c3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in SAD group; d1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in SAD group; d3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in SAD group; e1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in LSAD group; e2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3,

FEF25-75%, FEF50%, and FEF75% were correlated with PC₂₀ with the coefficient of 0.224 (95%CI 0.154–0.291), 0.282 (95%CI 0.206–0.350), 0.291 (95%CI 0.217–0.359), 0.251 (95%CI 0.174–0.321), respectively, (all *p*<0.001, Table 3), Of note, small airway function parameters, especially FEF50%, showed a slightly higher correlation level with PC₂₀ than FEV₁% (0.291 vs. 0.224, *p*=0.014). The correlation patterns of PC₂₀ with spirometry parameters varied among subgroups. In NLF group, weak positive correlations were observed between PC₂₀ and FEV₁% (r=0.151, 95%CI 0.078–0.224), FEF25-75% (r=0.249, 95%CI 0.165–0.322), FEF50% (r=0.255, 95%CI 0.177–0.330) and FEF75% (r=0.199, 95%CI 0.119–0.279) (all

p<0.001). Interestingly, FEF50% and FEF25-75% showed higher coefficients with PC₂₀ than FEV₁% (0.255 vs. 0.151, p=0.016, 0.249 vs. 0.151, p=0.021). However, the correlation was absent for FEF75% with PC₂₀ in the SAD group (r=0.137, p=0.096). Surprisingly, none of FEV₁%, FEF50% and FEF25-75% had a significant relation with PC₂₀ in LSAD group (p>0.05). Nevertheless, FEF75% still showed a moderate positive correlation with PC₂₀ (r=0.511, 95%CI 0.194–0.758, p=0.006) in the LSAD group (all data were presented in Table 3). After adjustment for FEV₁%, the correlations of PC₂₀ with small airway parameters were slightly reduced but still existed (all p<0.05). Furthermore, ROC curves for FEF25-75%,



Fig. 3 Relationships among small airway function parameters, FEV1%, FEV1/FVC% and PEF% of spirometry. — Represent sprometric parameter, Spearman correlation coefficient, p; a1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in overall group; a2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in overall group; a3, The relationships among FEF25-75%, FEF50%, FEF75% and PEF% in overall group; b1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in NLF group; b2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in NLF group; b3, The relationships among FEF25-75%, FEF50%, FEF75% and PEF% in NLF group; c1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LAD group; c2, The relationships among FEF25-75%, FEF50%, FEF75% and PEF% in NLF group; c3, The relationships among FEF25-75%, FEF50%, FEF75% and PEF% in LAD group; d1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in SAD group; e2, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in SAD group; e1, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e4, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC% in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC%, in LSAD group; e3, The relationships among FEF25-75%, FEF50%, FEF75% and FEV1/FVC%, feed expiratory vital capacity/forced expiratory vital capacity ratio; PEF%, peak expiratory flow in predicted; FEF50%, forced expiratory flow at 75% of FVC predicted; FEF25-75%, forced expiratory flow at 75% of FVC predicted; FEF25-75%, forced expiratory flow at 75% of FVC predicted; FEF25-75%, forced expiratory flow at 75% of FVC predicted; FEF25-75%, forced expiratory flow at 75% of FVC predicted; FEF25-75%, fo

		אווטוווכנו אשוי	מוווברבו אמות חוב רחווהל	ח ה		2				
	Overall(n=851)	đ	NLF(N = 613)	р	LAD(N=6)	р	SAD(N= 166)	р	LSAD(N = 66)	р
	r (95%Cl)		r (95%Cl)		r		r (95%CI)		r (95%Cl)	
FEV ₁ %	0.224 (0.154–0.291) ⁺	< 0.001	0.151 (0.078-0.224) [†]	<0.001	-0.783	0.118	0.173 (0.016–0.335) [‡]	0.035	-0.020 (-0.471-0.402)	0.923
FEV ₁ /FVC%	0.206 (0.129-0.278)	< 0.001	0.143 (0.060-0.227)	0.001	-0.112	0.858	0.096 (-0.082-0.253)	0.245	0.367 (-0.046-0.702)	0.059
PEF%	0.179 (0.104–0.251)	< 0.001	0.154 (0.078-0.231)	< 0.001	-0.447	0.450	-0.025 (-0.191-0.151)	0.766	0.204 (-0.259-0.619)	0.308
FEF50%	0.291 (0.217–0.359) [‡]	< 0.001	0.255 (0.177-0.330) [‡]	< 0.001	0.112	0.858	0.264 (0.111–0.419) [‡]	0.001	0.171 (-0.254-0.543)	0.393
FEF75%	0.251 (0.174–0.321) [†]	< 0.001	0.199 (0.119–0.279) [†]	<0.001	0.112	0.858	0.137 (-0.034-0.301)	0.096	0.511 (0.194–0.758)	0.006
FEF25-75%	0.282 (0.206–0.350)‡	< 0.001	0.249 (0.165–0.322)‡	< 0.001	0.112	0.858	0.207 (0.047–0.354) [‡]	0.011	0.332 (-0.021-0.621)	0.091
⁺ [‡] : the different syn	upol in the same column in	dicated a signifi	icant difference between th	ie two correla	stion coefficients (p<0.	05), same letter	s indicated no difference b	etween the t	wo correlation coefficients	(p>0.05);
FEV ₁ %, forced expira	story volume in 1 s in predic	:ted; FEV ₁ / FVC,	FEV1/ FVC%, forced expirato	ory vital capa	city/forced expiratory	vital capacity ra	itio; PEF, peak expiratory flo	w, FEF50%, fo	orced expiratory flow at 50	% of vital
capacity; FEF75%, fo	rced expiratory flow at 75% (of vital capacity,	; FEF25-75%, forced expirato	iry flow betwo	een 25% and 75% of vit	al capacity; PC ₂	o, value of the provocative c	oncentration	of methacholine that caus	ing a 20%

all in FEV; Overall, the whole study population, NLF, normal lung function; LAD, large airway dysfunction; SAD; small airway dysfunction; LSAD, large and small airway dysfunction

FEF50% and FEF75% in predicting moderate to severe AHR showed areas under the curve (AUCs) was 0.796, 0.783, 0.738, respectively, with the optimal cut-off for FEF25-75% was 72.55% (specificity 0.68, sensitivity 0.82), for FEF50% was 71.7% (specificity 0.72, sensitivity 0.70), and for FEF75% was 64.7% (specificity 0.70, sensitivity 0.67). When combined, FEF25-75% and FEF75% had a higher AUC of 0.802 in predicting moderate to severe AHR, with a specificity of 0.57 and sensitivity of 0.93 (Fig. 4).

Discussion

This study demonstrated that FEF75% was the most significantly decreased parameter of small airway function parameters measured by spirometry in these preschool asthmatic children, despite 91.5% (779 of 851) of these patients had $FEV_1 \approx 80\%$. The prevalence of SAD was 19.5%, and the incidence of LSAD was 7.8%. Children with SAD were more likely to have a family history of asthma, more severe airflow obstruction, higher level of AHR and lower values of FEV₁%, FEV₁/FVC%, PEF% and PC₂₀ compared to those with NLF. Further analysis showed that FEF25-75%, FEF50% and FEF75% were strongly correlated with FEV₁%, FEV₁/FVC% and PEF%. Additionally, Small airway function parameters were found to be correlated with PC20 and were good predictors for moderate to severe AHR. In general, the study suggested that small airway function parameters were associated with airway dysfunction, particularly in patients with SAD, which provides supportive evidence for the need to pay attention to small airway function during the management of pediatric asthmatic patients.

Chronic airway inflammation, which affecting both the large and small airways, is a major factor in the development of asthma and is responsible for causing airflow limitation [1]. Guidelines [2, 25] recommend that FEV1 and FEV1/FVC serve as indices in estimating airway obstruction. However, the airflow limitation observed in children differs from that in adults. Several studies demonstrated that as the disease progresses, children were less likely to experience fixed airflow reduction because of the relatively short course of the disease and their FEV₁% values were not easily impaired [15]. Our results showed that 91.5% (779 of 851) patients had $\text{FEV}_1\% \ge 80\%$, but had varying degrees of reduced terminal airflow, with the highest abnormal rate observed for FEF75%, which was consistent with previous studies [34, 35]. This phenomenon suggests that the small airway dysfunction is involved in the early stages of asthma, even in the absence of obvious large airway impairment. Moreover, small airway function parameters appear to be more sensitive in estimating airway dysfunction in asthmatic children. Of these preschool asthmatic children, 19.5% (166 of 851) had small airway dysfunction, which is much lower than



Fig. 4, ROC of small airway function parameters in predicting moderate to severe AHR (N = 753). (A) ROC of single small airway function parameter in predicting moderate to severe AHR; (B) ROC of combination of small airway function parameters in predicting moderate to severe AHR; ROC, receiver operating characteristic curve; FEF25-75%, forced expiratory flow between 25% and 75% of vital capacity; FEF50%, forced expiratory flow at 50% of vital capacity; FEF75%, forced expiratory flow at 75% of vital capacity; AHR, airway hyperresponsiveness

that in the adult studies (50 -90%) [18]. This difference is likely related to different physiological parameters used to assess small airway function. Additionally, small airways are major sites of persistent type 2 inflammation and airway remodeling, which relates to more loss of lung function with aging [14, 35]. Our study also found lung function impairment was more significant in elder asthmatic children. In addition, compared with children with NLF, children with SAD had significantly decreased FEV₁%, FEV₁/FVC%, and PEF%. Further analysis demonstrated that FEV₁%, FEF50%, FEF75% and FEF25-75% were near the lower limit of normal values in patients with LAD with or without a single abnormal small airway parameter. As FEV₁ reflects both flow and volume components, airflow limitation may induce a decrease in FEF75%, FEF50% or FEF25-75%. This phenomenon was more pronounced in the LSAD groups, in which small airway function decreased remarkably. To some extent, this result suggests small airways involvement is presented in varying degrees in asthmatic patients, particularly in those with severe asthmatic patients.

Our results indicated that there were similar positive correlations between small and large airway function parameters study, which were consistent with other studies [16, 21, 34]. In addition, the variables are not likely to form a complete straight-line trend from the correlation curve fitting diagrams. The curve is steeper in the stage of small airway function decline, and as the small airway function rises to normal, the curve tends to be gentler. These findings suggest that inflammation affects both large and small airway airflow reduction to different degrees and the process of airway obstruction may be distributed unevenly. Pathological studies in asthmatics have shown airway inflammation is a heterogeneous process. Small airways are the major sites where more inflammatory cells (such as T lymphocytes, macrophages, and eosinophils) infiltrated than that in large airways [36-38]. The severe airflow limitation is in line with persistent airway inflammation. Those inflammatory cells accumulate in small airways and involve large airways and alveoli gradually, which could damage airway elastic tissue via the secretion of perforins and granzyme, contributing to airway dysfunction and remodeling [39– 41]. Additionally, small airway dysfunction could lead to alterations in the pressure and flow within the airways, which increases shear stresses on the bronchial epithelium and promotes airway remodeling [42, 43]. Small airway dysfunction could also lead to changes in lung mechanics, such as reduced lung compliance, which can cause increased stress on the larger airways [44, 45]. These interrelated mechanisms may explain why small airway dysfunction contributes to the development of large airway dysfunction. However, the pathophysiological relationship between small airway dysfunction and large airway impairment is complex and multifactorial. Future researches are required to elucidate the precise mechanisms involved. As small airways remodeling begins at early stage, anti-asthma treatment, particularly for those with small airway function impairment, may contribute to improved large airway function in the early stage and better-preserved lung function into adulthood. Randomized controlled trials have shown approximately half of extrafine-formulation, one of the small particle sizes of inhaled drugs that can deposit in the peripheral airway, can achieve similar functional outcomes compared with non-extrafine formulations [46, 47]. However,

there is currently little direct strong evidence in this area in asthmatic children.

Evidence have shown the decline of FEV₁ is an independent risk factor for asthma exacerbation, and GINA has provided detailed recommendations for FEV1 and PEF as indices for assessing disease conditions and treatment [2]. However, these parameters do not reflect small airway function well [17], especially in asthmatic children [16]. FEF25-75% and FEF50% seem to be better parameters for reflecting small airway function, airflow obstruction and disease severity in asthmatic children than FEV₁% and FEV₁/FVC% [15, 34, 48]. Our findings also showed small airway parameters (FEF25-75%, FEF50%, FEF75%) were more strongly correlated with airflow limitation and AHR in preschool asthmatic children. Nevertheless, a large retrospective study [22] showed that FEF25-75% and FEF75% fail to contribute useful information to the clinical assessment of disease severity. This large study cohort was characterized by greater disease heterogeneity, and 71% of the 3 to 10-year-old children had artifacts in the flow-volume curve or did not achieve an individual optimal inspiratory or expiratory status, which could affect the lung function results and research conclusion. Besides, the study did not further investigate the relationship between small airway function and the intensity of AHR, which may be the reason for the inconsistency with our findings.

Airway hyperresponsiveness is a characteristic feature of the asthma development that has been demonstrated to be associated with airway inflammation and small airway ventilation heterogeneity [49]. Research indicates small airway dysfunction, independently of FEV₁, is related to the severity of AHR in asthma [50]. FEF25-75% was found to be highly related to methacholine responsiveness and the slope of the methacholine dose-response in asthmatic children with normal FEV₁% [51, 52]. Moreover, FEF50% is an independent predictor of the provocative dose of histamine-associate 20% fall in FEV₁ [50]. Our findings are consistent with previous studies [50-52] that FEF25-75% and FEF50% have higher correlation coefficients with PC20 in asthmatic children compared with FEV1%. And a higher level of AHR and airflow obstruction were observed in children with SAD compared to those in NLF group, even though their FEV₁% was comparable. Thus, small airway function parameters may more accurately reflect the airway function status. Furthermore, our results showed that children had the worst clinical status, including a highest degree of airflow obstruction and AHR when the small airway function was significantly impaired with the presence of FEV₁% decreased (LSAD group). These findings suggest severe SAD may influence large airway dysfunction and thus contributes to worse clinical manifestation.

To our knowledge, this study complied with our published protocol [53] was the first to investigate the role of small airway dysfunction in a large group of preschool asthmatic children using spirometry. In addition, instead of using one small airway parameter, we combined all three small airway functional parameters of spirometry to evaluate small airway dysfunction and studied the complex correlation of spirometry parameters in preschool asthmatic children. However, our research was a cross-sectional study which can only reflect the current state of lung function in preschool children and cannot explain the effect of persistent SAD on the development of large airway function and the prognosis of the disease. Moreover, as data on confounding factors such as management, passive smoking, exposure to PM2.5 and physical inactivity were lacking [54], we cannot exclude the potential effects of these confounding factors on spirometry. Future studies should consider these information to better interpret the impacts on spirometry parameters.

Conclusion

Overall, our findings showed small airway dysfunction is strongly associated with abnormal large airway function, airflow obstruction and AHR in preschool asthmatic children. FEF25-75%, FEF50% and FEF75% are sensitive parameters in reflecting airway dysfunction and AHR in asthmatic preschool patients with normal FEV₁%. These small airway function parameters could be used as supplementary indicators in the assessment of children with large airway dysfunction. Therefore, management strategies for preschool asthmatic children, especially those with normal FEV_1 %, should focus on small airway function.

Abbreviations

71001011010	
AHR	Airway hyperresponsiveness
ATS	American Thoracic Society
AUC	Area under the curve
BMI	Body mass index
ERS	European Respiratory Society
FEV ₁	Forced expiratory volume in 1 s in predicted
FEV ₁ /FVC	Forced expiratory volume in 1 s/forced expiratory vital capacity ratio
FEF50	Forced expiratory flow at 50% of forced vital capacity predicted
FEF75	Forced expiratory flow at 75% of forced vital capacity predicted
FEF25-75	Forced expiratory flow between 25% and 75% of forced vital
	capacity predicted
GINA	Global Initiative for Asthma
IQR	Interquartile range
LAD	Large airway dysfunction
LSAD	Large and small airway dysfunction
NLF	Normal lung function
PEF	Peak expiratory flow
ROC	Receiver operating characteristic
SAD	Small airway dysfunction
PC ₂₀	Value of the provocative concentration of methacholine that
	caused a 20% fall in FEV_1

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12890-023-02515-3.

Supplementary Material 1	
--------------------------	--

Supplementary Material 2

Acknowledgements

We appreciate the substantial support of the Children's Hospital of Chongqing Medical University.

Authors' contributions

Zhengxiu Luo supervised the research design, statistical analysis, manuscript review and interpretations. Liangqin Yi participated in research design, data collection and organization, statistical analysis, manuscript writing and interpretation. Yan Zhao conducted statistical analysis and manuscript writing. Ziyao Guo were involved in data collection and organization and manuscript review. Qinyuan Li participated in research design, statistical analysis and manuscript review. Guangli Zhang and Xiaoyin Tian are the key researches in patients's clinical information collection and organization. Ximing Xu participated in research design analysis. All authors read and approved the final version of the manuscript.

Funding

This work was supported by National Clinical Research Center for Child Health and Disorders (No. NCRCCHD-2020-GP-05; No.NCRCCHD-2021-YP-01) and Ministry of Education Key Laboratory of Child Development and Disorders (No. GBRP-202112).

Data Availability

Data are available on request to the corresponding author.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

This study was approved by the institutional review board of the Children's Hospital of Chongqing Medical University (File No. (2022)186). The requirement of obtaining informed consent was waived due to the retrospective design of the study. All methods were performed in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Received: 10 March 2023 / Accepted: 8 June 2023 Published online: 20 June 2023

References

- 1. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma Lancet. 2018;391(10122):783–800.
- 2. Global Initiative for Asthma. Global strategy for asthma management and prevention [Available from: www.ginasthma.org.
- Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278(25):1355–60.
- 4. Halwani R, Al-Muhsen S, Hamid Q. Airway remodeling in asthma. Curr Opin Pharmacol. 2010;10(3):236–45.
- Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol. 2007;120(5):997–1009. quiz 10 – 1.
- Roche WR. Inflammatory and structural changes in the small airways in bronchial asthma. Am J Respir Crit Care Med. 1998;157(5 Pt 2):191–4.
- Cottini M, Lombardi C, Micheletto C. Small airway dysfunction and bronchial asthma control: the state of the art. Asthma Res Pract. 2015;1:13.

- Shi Y, Aledia AS, Tatavoosian AV, Vijayalakshmi S, Galant SP, George SC. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol. 2012;129(3):671–8.
- Schulze J, Biedebach S, Christmann M, Herrmann E, Voss S, Zielen S. Impulse oscillometry as a predictor of Asthma Exacerbations in Young Children. Respiration. 2016;91(2):107–14.
- Keen C, Olin AC, Wennergren G, Gustafsson P. Small airway function, exhaled NO and airway hyper-responsiveness in paediatric asthma. Respir Med. 2011;105(10):1476–84.
- Arıkoglu T, Unlu A, Yıldırım DD, Kuyucu S. The airway hyperresponsiveness to methacholine may be predicted by impulse oscillometry and plethysmography in children with well-controlled asthma. J Asthma. 2018;55(11):1166–73.
- 12. Lajunen K, Kalliola S, Kotaniemi-Syrjänen A, Sarna S, Malmberg LP, Pelkonen AS, et al. Abnormal lung function at preschool age asthma in adolescence? Ann Allergy Asthma Immunol. 2018;120(5):520–6.
- Skylogianni E, Triga M, Douros K, Bolis K, Priftis KN, Fouzas S, et al. Small-airway dysfunction precedes the development of asthma in children with allergic rhinitis. Allergol Immunopathol (Madr). 2018;46(4):313–21.
- Koefoed HJL, Zwitserloot AM, Vonk JM, Koppelman GH. Asthma, bronchial hyperresponsiveness, allergy and lung function development until early adulthood: a systematic literature review. Pediatr Allergy Immunol. 2021;32(6):1238–54.
- Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med. 2004;170(4):426–32.
- Goldberg S, Springer C, Avital A, Godfrey S, Bar-Yishay E. Can peak expiratory flow measurements estimate small airway function in asthmatic children? Chest. 2001;120(2):482–8.
- Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med. 1978;298(23):1277–81.
- Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med. 2019;7(5):402–16.
- Lebecque P, Kiakulanda P, Coates AL. Spirometry in the asthmatic child: is FEF25-75 a more sensitive test than FEV1/FVC? Pediatr Pulmonol. 1993;16(1):19–22.
- Gelb AF, Zamel N. Simplified diagnosis of small-airway obstruction. N Engl J Med. 1973;288(8):395–8.
- Qin R, An J, Xie J, Huang R, Xie Y, He L et al. FEF(25–75)% Is a More Sensitive Measure Reflecting Airway Dysfunction in Patients with Asthma: A Comparison Study Using FEF(25–75)% and FEV(1). J Allergy Clin Immunol Pract. 2021;9(10):3649-59.e6.
- Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43(4):1051–8.
- 23. Lukic KZ, Coates AL. Does the FEF25-75 or the FEF75 have any value in assessing lung disease in children with cystic fibrosis or asthma? Pediatr Pulmonol. 2015;50(9):863–8.
- 24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.
- 25. Pediatr CJAC. Series guidelines for pediatric pulmonary function (part II): lung volume and spirometry. Chin J Appl Clin Pediatr. 2016.
- Zhong Y, Li L, Chen R, Zheng Q. Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: a systematic review and metaanalysis. Respirology. 2022;27(3):194–201.
- Knihtilä H, Kotaniemi-Syrjänen A, Pelkonen AS, Mäkelä MJ, Malmberg LP. Small airway function in children with mild to moderate asthmatic symptoms. Ann Allergy Asthma Immunol. 2018;121(4):451–7.
- Jian W, Gao Y, Hao C, Wang N, Ai T, Liu C, et al. Reference values for spirometry in chinese aged 4–80 years. J Thorac Dis. 2017;9(11):4538–49.
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.
- Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the american thoracic society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309–29.
- Pediatr CJAC. Series Guidelines for Pediatric Pulmonary Function (Part II):Bronchial Provocation Test. Chinese journal of applied clinical pediatrics. 2017.

- 32. Pediatr CJAC. Expert consensus on evaluation and treatment of small airway dysfunction in children with asthma. Chin J Appl Clin Pediatr. 2021.
- Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39–44.
- Francisco B, Ner Z, Ge B, Hewett J, König P. Sensitivity of different spirometric tests for detecting airway obstruction in childhood asthma. J Asthma. 2015;52(5):505–11.
- Xuan W, Peat JK, Toelle BG, Marks GB, Berry G, Woolcock AJ. Lung function growth and its relation to airway hyperresponsiveness and recent wheeze. Results from a longitudinal population study. Am J Respir Crit Care Med. 2000;161(6):1820–4.
- Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J. 1997;10(2):292–300.
- Dolhnikoff M, da Silva LF, de Araujo BB, Gomes HA, Fernezlian S, Mulder A, et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol. 2009;123(5):1090. 7.e1.
- Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol. 1998;101(3):386–90.
- Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(10):1404–9.
- Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53.
- Chrysofakis G, Tzanakis N, Kyriakoy D, Tsoumakidou M, Tsiligianni I, Klimathianaki M, et al. Perforin expression and cytotoxic activity of sputum CD8 + lymphocytes in patients with COPD. Chest. 2004;125(1):71–6.
- 42. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–21.
- Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59.
- Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration. 2012;84(2):89–97.
- Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(5):434–9.

- Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007;29(4):682–9.
- Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182–8.
- Comberiati P, Spahn JD, Paull K, Faino A, Cherniack R, Covar RA. Lung mechanical properties distinguish children with asthma with normal and diminished lung function. Clin Exp Allergy. 2020;50(4):453–62.
- Downie SR, Salome CM, Verbanck S, Thompson B, Berend N, King GG. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. Thorax. 2007;62(8):684–9.
- Telenga ED, van den Berge M, Ten Hacken NH, Riemersma RA, van der Molen T, Postma DS. Small airways in asthma: their independent contribution to the severity of hyperresponsiveness. Eur Respir J. 2013;41(3):752–4.
- Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF Jr, Szefler SJ, et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J Allergy Clin Immunol. 2010;126(3):527–34.e1-8.
- 52. Ownby DR, Peterson EL, Johnson CC. Factors related to methacholine airway responsiveness in children. Am J Respir Crit Care Med. 2000;161(5):1578–83.
- 53. Li Q, Zhou Q, Li Y, Liu E, Fu Z, Luo J, et al. The predictive role of small airway dysfunction and airway inflammation biomarkers for asthma in preschool and school-age children: a study protocol for a prospective cohort study. Transl Pediatr. 2021;10(10):2630–8.
- Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, et al. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020;8(11):1081–93.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.